– Reuters
RBC Capital Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $118
RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:EW) with a Outperform and lowers the price target from $128 to $118.
Related Posts
Telsey Advisory Group Maintains Market Perform on Children’s Place, Lowers Price Target to $44
Telsey Advisory Group analyst Dana Telsey maintains Children's Place (NASDAQ:PLCE) with a Market Perform and lowers the price target from $46 to $44.
Zymeworks Announces Filing And Mailing Of Materials For The Special Meeting To Approve Redomicile To Delaware
Redomicile anticipated to enhance long-term value for securityholders, provide opportunities for increased value of Zymeworks common shares, and better position the Company for future growth
Zymeworks Board
Goldman Sachs Maintains Neutral on Canadian Solar, Raises Price Target to $43
Goldman Sachs analyst Brian Lee maintains Canadian Solar (NASDAQ:CSIQ) with a Neutral and raises the price target from $38 to $43.